Evidence map›Paper›PMID 33067063›Full record

ArticleThe American journal of emergency medicine2021

Interhospital transportation of a COVID-19 patient undergoing veno-venous extracorporeal membrane oxygenation by helicopter.

Taro Imaeda, Noriyuki Hattori, Ryuzo Abe, Shinya Iwase, Daiki Saito, Kazuhisa Koizumi, Wansiri Chaisirin, Toshibumi Taniguchi, Taka-Aki Nakada

Open access · greenAbstract readCase Reports
In one paragraph

Article in The American journal of emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Taro ImaedaDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Noriyuki HattoriDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. Electronic address: hat@chiba-u.jp.
Ryuzo AbeDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. Electronic address: ryuzoabe@chiba-u.jp.
Shinya IwaseDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Daiki SaitoDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Kazuhisa KoizumiDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Wansiri ChaisirinDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Toshibumi TaniguchiDepartment of Infectious Diseases, Chiba University Hospital, Chiba, Japan. Electronic address: tosh-tanig@chiba-u.jp.
Taka-Aki NakadaDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. Electronic address: taka.nakada@nifty.com.
Chiba University · JPChiba University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some coronavirus disease 2019 (COVID-19) patients develop rapidly progressive acute respiratory distress syndrome and require veno-venous extracorporeal membrane oxygenation (V-V ECMO). A previous study recommended the transfer of ECMO patients to ECMO centers. However, because of the pandemic, a limited number of ECMO centers are available for patient transfer. The safe long-distance interhospital transport of these patients is a concern. To minimize transportation time, helicopter use is a suitable choice. We report the first case of a COVID-19 patient on V-V ECMO, transferred to our ECMO center by helicopter. A 45-year-old man with rheumatoid arthritis history, treated with immunosuppressants, presented with fever and sore throat. He was diagnosed with COVID-19 following a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test result and was subsequently prescribed favipiravir. However, his respiratory failure progressively worsened. On day 10 of hospitalization at the previous hospital, he was intubated, and we received a request for ECMO transport on the next day. The ECMO team, who wore personal protective equipment (N95 respirators, gloves, gowns, and face shields), initiated V-V ECMO in the referring hospital and safely transported the patient by helicopter. The flight time was 7 min. He was admitted to the intensive care unit of our hospital and received tocilizumab. He was discharged on hospital day 31 with no significant sequelae. In this case report, we discuss important factors for the safe and appropriate interhospital transportation of COVID-19 patients on ECMO as well as staff and patient safety during helicopter transportation.

Indexed as

AircraftIntensive Care UnitsPandemicsCOVID-19Extracorporeal Membrane OxygenationHumansMaleMiddle AgedPatient TransferTransportation of PatientsCoronavirusFavipiravirMobile ECMOPrimary transportTocilizumab

Identifiers

PMID33067063
PMCPMC7836635
OpenAlexW3090021505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.